These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

The Irish Patients Association is calling on parents and guardians of children to join together with them in ‘Flunion’ in the ...

Pfizer's RSV rollback comes as the space has grown increasingly crowded. Besides marketed vaccines, Sanofi and AstraZeneca sell an antibody to protect infants, with Merck & Co. now eying a piece of ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the ... FluMist is anticipated to launch for the 2024-2025 flu season. Physician’s ...

Anyone also entitled to the flu jab, external will be offered this at the same time. Patients who are also entitled to the respiratory syncytial virus (RSV) vaccine, external will not usually be ...

Last month, following the inaugural Childhood Influenza Policy Steering Committee (CIPSC), organised and funded by AstraZeneca ... there is no one-size fits all vaccine programmes - national ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

AstraZeneca reaffirmed its commitment to combating infectious ... In addition, vaccine effectiveness data on FluMist, the only self-administered flu vaccine approved in the US, will be presented. Real ...

Rwanda has been stepping up measures to combat Rift Valley Fever (RVF) following the country's second outbreak in two years, ...

Operator Good day, and welcome to the OPKO Health third quarter of 2024 financial results conference call. All participants ...